Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
Assess the comparative safety and tolerability of two SAR153191 (REGN88) drug products after
a single dose administration in rheumatoid arthritis patients.
Secondary Objective:
Assess the comparative pharmacokinetic profiles of the two SAR153191 (REGN88) drug products
after a single dose administration in rheumatoid arthritis patients.